Cirius Therapeutics

Cirius Therapeutics is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of non-alcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. With its novel insulin sensitization mechanism, MSDC-0602K has the potential to address the underlying pathophysiology of NASH.